Celularity Inc. (NASDAQ:CELUW) Sees Large Decrease in Short Interest

by · The Cerbat Gem

Celularity Inc. (NASDAQ:CELUW – Get Free Report) was the target of a significant decline in short interest in the month of December. As of December 15th, there was short interest totaling 2,243 shares, a decline of 23.4% from the November 30th total of 2,930 shares. Based on an average daily trading volume, of 9,172 shares, the short-interest ratio is presently 0.2 days. Based on an average daily trading volume, of 9,172 shares, the short-interest ratio is presently 0.2 days.

Celularity Price Performance

NASDAQ CELUW traded down $0.00 during midday trading on Wednesday, hitting $0.02. The company had a trading volume of 2,000 shares, compared to its average volume of 16,042. The firm has a 50-day moving average price of $0.02 and a 200-day moving average price of $0.04. Celularity has a twelve month low of $0.01 and a twelve month high of $0.75.

Celularity Company Profile

(Get Free Report)

Celularity, Inc is a clinical-stage biotechnology company headquartered in Florham Park, New Jersey, that specializes in the development and commercialization of allogeneic “off-the-shelf” cell therapies derived from postpartum placental cells. Leveraging a proprietary platform of placental- and umbilical-derived cells, the company seeks to deliver immune-modulatory, regenerative and anti-inflammatory treatments across oncology, immunology and other therapeutic areas. By harnessing the natural properties of placental cells, Celularity aims to overcome the limitations of autologous therapies and scale production to serve a broad patient population.

The company’s pipeline includes CYNK-001, an investigational natural killer (NK) cell therapy being evaluated for hematological malignancies and solid tumors, as well as other cell-based programs targeting viral infections and tissue repair.

See Also